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Abstract In order to identify receptor molecules that partici-
pate in the growth and di¡erentiation of chondrocytes, we
cloned a number of cDNA fragments from HCS-2/8 chondro-
cytic cells, by using tyrosine kinase-speci¢c primers for ampli-
¢cation. The mRNA expression of one such receptor, ErbB4,
was increased by connective tissue growth factor/hypertrophic
chondrocyte-speci¢c gene product (CTGF/Hcs24), which pro-
motes all stages of the endochondral ossi¢cation in vitro.
ErbB4 expression was observed through all stages of chondro-
cytic di¡erentiation in vitro, corresponding to the wide distribu-
tion of CTGF/Hcs24 target cells. Furthermore, positive signals
for erbB4 mRNA were detectable throughout most populations
of chondrocytes, in growth and articular cartilage in vivo. These
results demonstrate for the ¢rst time that ErbB4 is expressed in
chondrocytes and may play some roles in chondrocytic growth
and di¡erentiation along with CTGF/Hcs24. 0 2002 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Endochondral ossi¢cation is a complex biological process
that determines the growth and ossi¢cation of longitudinal
bones, which tasks are accomplished by highly organized
layers of chondrocytes. This process is under the control of
a vast number of growth factors and cytokines. Previously, we
cloned cDNA fragments preferentially expressed in a human
chondrosarcoma-derived chondrocytic cell line, HCS-2/8 [1,2],
by use of the di¡erential display-polymerase chain reaction
(PCR) [3]. One of these cDNA fragments was identical to a
fragment of connective tissue growth factor/hypertrophic
chondrocyte-speci¢c 24 (CTGF/Hcs24) gene [4]. CTGF/
Hcs24 is a cysteine-rich, heparin-binding protein whose gene
belongs to the immediate early gene family known as CCN
family that is composed of cyr61, ctg, nov [5^8], ctgf-3/wisp-2/
rcop-1 [9,10], wisp-1/elm-1 [11], and wisp-3 [12]. CTGF/Hcs24
was shown to be mitogenic for ¢broblasts in vitro and its gene
expression in human ¢broblasts was induced by transforming
growth factor (TGF)-L [13]. Because of these characteristics, it
has been implicated in human atherosclerosis and ¢brotic dis-
orders such as systemic scleroderma [14]. However, surpris-
ingly, we found that recombinant CTGF/Hcs24 (rCTGF/
Hcs24) promoted the growth and di¡erentiation of chondro-
cytes at all stages in vitro and that its expression was highest
in hypertrophic chondrocytes of growth cartilage among var-
ious normal tissues in vivo [15]. CTGF/Hcs24 expression in
chondrocytes was induced by the addition of TGF-L or bone
morphogenetic protein-2 [3]. These ¢ndings strongly suggest
that CTGF/Hcs24 may play important roles in endochondral
ossi¢cation.
In the earliest studies, binding of partially puri¢ed CTGF/
Hcs24 to the platelet-derived growth factor (PDGF) type B
receptor was suggested [4], but neither direct binding between
the two, nor intracellular signal transduction was described.
Based on the data that the mRNA expression of both CTGF/
Hcs24 and PDGF type A receptor was upregulated in sclero-
derma ¢broblasts, it was also suggested that CTGF/Hcs24
and PDGF type A receptors may have some interactions
[14]. However, PDGF displays no such e¡ects on chondro-
cytes as caused by CTGF/Hcs24, and thus the signi¢cance of
any CTGF/Hcs24^PDGF receptor interaction would be ques-
tionable. Another study indicated that CTGF/Hcs24 and
Cyr61 directly bound to integrin KVL3 and KIIbL3 on ¢bro-
blasts [16]. Cyr61 also induced adhesion of human ¢broblasts
mediated by integrin K6L1 interaction with cell-surface hepar-
an sulfate proteoglycans, and activated intracellular signaling
molecules [17]. Most recently, the low density lipoprotein re-
ceptor/K2 macroglobulin receptor was shown to be a speci¢c
receptor of CTGF/Hcs24 [18], but its function remains to be
clari¢ed.
In our previous study, we demonstrated speci¢c receptors
for CTGF/Hcs24 on HCS-2/8 cells [19] and found them to be
associated with protein kinase activity (Nishida et al., manu-
script in preparation). In this study, we cloned a number of
tyrosine kinase-type DNA fragments from HCS-2/8 cells by
using tyrosine kinase-speci¢c primers. We also investigated
the interaction between CTGF/Hcs24 and one of its putative
receptors, ErbB4. This is the ¢rst report to show that ErbB4,
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a neuregulin (NRG) receptor, is expressed in both growth and
articular cartilage in vivo.
2. Materials and methods
2.1. Cell culture
Four human cell lines were used in this study. A chondrosarcoma-
derived chondrocytic cell line (HCS-2/8), a squamous cell carcinoma
cell line (A431), a breast cancer cell line (MDA231) and a ¢brosarco-
ma cell line (HT1080) were cultured in Dulbecco’s modi¢ed minimum
essential medium (DMEM) (Nissui Pharmaceutical, Tokyo, Japan)
supplemented with L-glutamine (2 mM) and 10% fetal bovine serum
(FBS). CTGF/Hcs24 stimulation of con£uent HCS-2/8 cell cultures
was performed with a rCTGF/Hcs24 at a concentration of 50 ng/ml.
A murine cell line, ATDC5 cells were cultured in DMEM/Ham’s F-12
(1:1) hybrid medium (ICN Biomedicals, Inc., Costa Mesa, CA, USA)
supplemented with 5% FBS (ICN Biomedicals, Inc., Costa Mesa, CA,
USA), 10 Wg/ml human transferrin (Roche Molecular Biochemicals,
Indianapolis, IN, USA), and 3U1038 M sodium selenite (Sigma,
St. Louis, MO, USA). For induction of chondrogenesis, ATDC5 cells
were plated at a density of 6U104 cells/well in 6-well plates and
cultured for 22 days in the above medium supplemented with
10 Wg/ml of human recombinant insulin (Wako Pure Chemical,
Osaka, Japan). All of the cells were cultured in a 5% CO2 atmosphere
at 37‡C.
2.2. Cloning of cDNA fragments of tyrosine kinase-type receptors
Total RNA was isolated from con£uent cultures of HCS-2/8 cells
according to the method of Chomczynski et al. [20]. The RNA was
treated with DNase I at 37‡C for 30 min and was then reverse tran-
scribed to cDNA by using an oligo dT16 primer with AMV-derived
reverse transcriptase for 30 min at 42‡C. Next, the cDNA was ampli-
¢ed with Taq Gold polymerase (Applied Biosystems/Perkin Elmer,
Branchburg, NJ, USA) by using the following oligonucleotide primers
for the conserved segments of the kinase domains of tyrosine kinase-
type receptors: sense, 5P-GGAATTCCATCGIGATTTIGCIGCICG-
3P ; antisense, 5P-CCTCGAGATICCGTAGGTCCAIACGTC-3P. The
ampli¢cation conditions were as follow: 95‡C (10 min) for one cycle,
then 95‡C (30 s)^50‡C (30 s)^72‡C (30 s) for 40 cycles, and 72‡C (7
min) for one cycle. The PCR products were separated by agarose gel
electrophoresis. Next, these separated bands were excised from gels,
and subcloned into pCR-script plasmid vector (Stratagene, La Jolla,
CA, USA). Then, nucleotide sequences of these clones were deter-
mined by an automated DNA sequencing system (Applied Biosys-
tems/Perkin Elmer), and the sequence homology was analyzed, by
using the DDBJ homology search system BLAST.
2.3. Reverse transcriptase-mediated PCR (RT-PCR) analysis
From con£uent HCS-2/8 cells, total RNA was isolated 5, 15, 30, 60,
and 120 min after the addition of rCTGF/Hcs24 to the cultures, ac-
cording to the method of Chomczynski et al. [20]. From ATDC5 cells,
total RNA was isolated 2, 5, 8, 14, and 19 days after con£uence.
Isolation of total RNA was performed under standard tissue culture
conditions in the cases of A431, MDA231 and HT1080 cells. The
isolated total RNA (0.5 Wg) was treated with 20 U of DNase I at
37‡C for 30 min and was then reverse-transcribed to cDNA by using
oligo dT16 primers with AMV-derived reverse transcriptase for 30 min
at 42‡C. Thereafter, the cDNA was ampli¢ed with Taq Gold poly-
merase (Applied Biosystems/Perkin Elmer), using the following pairs
of oligonucleotide primers for erbB4 mRNA: forward (erbB4-sense),
5P-GACGAATTCCNATHAARTGGATGGC-3P ; reverse (erbB4-
antisense), 5P-CTGCTGTCAGCATCGATCAT-3P. The ampli¢cation
conditions were as follow: 95‡C (10 min) for one cycle then 95‡C
(30 s)^50‡C (30 s)^72‡C (30 s) for 45 cycles, and 72‡C (7 min) for
one cycle. RT-PCR analyses for CTGF/Hcs24, type X collagen, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH: control)
mRNAs were performed as described previously [15]. The PCR prod-
ucts were analyzed by agarose gel electrophoresis.
2.4. In situ hybridization and histological analyses
ICR mice (3 weeks old) were used for this study. The knee and
temporomandibular joints of the animals were removed and immedi-
ately immersed in 4% paraformaldehyde and kept in it for 24 h. Next,
the specimens were decalci¢ed with 10% ethylene diamine tetraacetic
acid for 2 weeks, embedded in para⁄n, and cut into 4-Wm sections.
The knee sections were hybridized with digoxigenin-labeled anti-sense
riboprobes for the coding region of the extracellular domain of erbB4
and the entire coding region of ctgf, as described previously [3]. La-
beled sense riboprobes were utilized for negative control experiments
to ensure the signal speci¢city. The same sections were also subjected
to nuclear staining with methylgreen.
3. Results
3.1. Screening and identi¢cation of the tyrosine kinase-type
receptor cDNA fragments expressed in HCS-2/8 cells
The conserved tyrosine kinase domain-encoding cDNA
Fig. 1. Conserved amino acid sequences and their corresponding cDNA sequences among the kinase domains of a variety of tyrosine kinase-
type receptors. The two sequences, one downstream and one upstream, utilized for designing oligonucleotide primers are shown in single-letter
codes. The resultant primers contained several deoxyinosines instead of mixed deoxyribonucleotides, as shown at the bottom. Abbreviations:
EGF-R, epidermal growth factor receptor; INS-R, insulin receptor; PDGF-R, platelet-derived growth factor receptor; FGF-R, ¢broblast
growth factor receptor.
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fragments were ampli¢ed from total RNA isolated from HCS-
2/8 cells by RT-PCR utilizing two primers comprising several
deoxyinosines for ambiguous nucleotide sequences (Fig. 1).
The ampli¢ed product was then subcloned into the pCR-script
vector, by using a commercially available kit (Stratagene).
Among a number of colonies obtained, 398 clones were sub-
jected to the initial screening to verify the insertion of the
cDNA fragment. As a result, 181 clones were forwarded for
nucleotide sequencing after puri¢cation through an ion-ex-
change column (Qiagen, Hilden, Germany). Identity of the
obtained nucleotide sequences was determined by using the
DDBJ homology search system BLAST. Consequently,
29 clones were identi¢ed as fragments of the macrophage
colony-stimulating factor receptor (M-CSFR) gene, nine
clones as portions of the human EPH-like receptor protein
kinase 8 (HEK8) gene, and one clone was found to be a
fragment of the NRG receptor (ErbB4) gene [21].
3.2. Upregulation of erbB4 gene expression by CTGF
Next, we evaluated the interaction of these tyrosine kinase-
type receptors with CTGF/Hcs24 by adding exogenous
rCTGF/Hcs24 [15] to HCS-2/8 cell cultures. In previous re-
ports, 50 ng/ml of rCTGF/Hcs24 was e¡ective enough to dis-
play biological function on chondrocytic cells. Therefore,
HCS-2/8 cells were treated with this ¢xed dose of rCTGF/
Hcs24, and total RNA was harvested following a time course.
A pair of erbB4 primers that recognized the erbB4 mRNA of
multiple mammalian species was prepared. RT-PCR analysis
with these primers clearly showed rapid induction of erbB4
gene expression in HCS-2/8 cells upon CTGF/Hcs24 stimula-
tion (Fig. 2A). Similar results were obtained from another
series of experiments with rabbit primary growth cartilage
chondrocytes (data not shown). The cooperative expression
of erbB4 and ctgf genes was con¢rmed by analyzing their
gene expression patterns in other non-chondrocytic cell lines
(Fig. 2B). A squamous cell carcinoma cell line, A431, showed
no detectable gene expression of either ctgf, or erbB4, whereas
a CTGF/Hcs24-producing breast cancer cell line, MDA231,
displayed a signi¢cant level of erbB4 mRNA expression.
Under the same experimental conditions, ctgf gene expression
was marginally detectable in the ¢brosarcoma cell line
HT1080, which also gave a faint signal for erbB4 mRNA.
As such, the data indicated that the gene expression of the
tyrosine kinase-type receptor erbB4 was signi¢cantly upregu-
lated by CTGF/Hcs24, which action may represent the upreg-
ulation of receptors by their speci¢c ligands. However, no
upregulation was observed in the case of HEK8 by CTGF/
Fig. 2. A: Induction of erbB4 gene expression by rCTGF/Hcs24 in
HCS-2/8 cells. Total RNA was sampled at each time point after the
addition of rCTGF/Hcs24 (50 ng/ml) and analyzed by RT-PCR.
GAPDH gene expression was analyzed and displayed as an internal
control. Similar results were obtained with rabbit primary growth
cartilage cells (data not shown). B: Concomitant expression of ctgf
and erbB4 among human tumor-derived cell lines other than chon-
drocytic HCS-2/8. A431, MDA231, and HT1080 originated from
human squamous cell carcinoma, breast cancer, and ¢brosarcoma,
respectively.
Fig. 3. Comparative analysis of the expression time course of type X collagen, CTGF/Hcs24 and ErbB4 genes during chondrocytic di¡erentia-
tion. After reaching con£uence, ATDC5 cells were maintained under di¡erentiation-inducing cell culture conditions as described in Materials
and Methods. Total RNA was isolated at the indicated postcon£uent days. ErbB4 gene expression was observed regardless of the di¡erentia-
tion stage. These analyses were repeated at least twice with comparable results, and a set of typical data are displayed here.
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Hcs24 stimulation (data not shown). Also, no remarkable
¢ndings were obtained for any M-CSFR^CTGF/Hcs24 inter-
action.
3.3. Expression of erbB4 gene along with chondrocytic
di¡erentiation
According to our previous ¢ndings, ctgf expression was
restricted to terminally di¡erentiated hypertrophic stages,
whereas its speci¢c receptors were displayed in immature to
mature chondrocytes, suggesting CTGF/Hcs24-independent
induction of such receptors in cartilage. Thus, we analyzed
the erbB4 gene expression following the course of in vitro
di¡erentiation of the murine chondrocytic ATDC5 cell line.
Therefore, unlike the case of tumor cell lines in Fig. 2B, ex-
pression patterns of ctgf and erbB4 were not expected to be
parallel in this experiment. Under these culture conditions,
expression of type X collagen mRNA gradually increased
along with time, representing the induction of di¡erentiation.
After day 8, late-phase expression of ctgf was strongly in-
duced. These ¢ndings represent terminal di¡erentiation of
those cells towards hypertrophy. In contrast to such di¡er-
ential expression of the ctgf gene, the erbB4 gene appeared
to be expressed constitutively until the onset of hypertrophy,
which is consistent with the ubiquitous demonstration of
CTGF/Hcs24 receptor(s) among chondrocytes in growth car-
tilage.
3.4. Expression of erbB4 in growth and articular cartilage in
vivo
Based on the results obtained from the in vitro experiments,
we subsequently carried out in situ hybridization analysis of
erbB4 gene expression and con¢rmed that chondrocytes in
growth plate and articular cartilage did express erbB4 in
vivo. Except in the late hypertrophic zones, erbB4 expression
was observed in almost all of the di¡erentiation stages of
chondrocytes in the epiphysial growth plate cartilage, which
is in sharp contrast to the restricted expression of ctgf in the
hypertrophic zone (Fig. 4) [3]. These ¢ndings are consistent
with the results in Fig. 3, demonstrating di¡erent expression
patterns of ctgf and erbB4 along the course of chondrocytic
di¡erentiation. In articular cartilage, erbB4 and ctgf were ex-
pressed sporadically in chondrocytes near the joint surface
and were highly expressed in the chondrocytes further
down, which morphologically correspond to the proliferative
and prehypertrophic chondrocytes. The negative control with
each sense probe gave no signi¢cant staining.
4. Discussion
In seeking speci¢c receptors for CTGF/Hcs24 on chondro-
cytes, we found that the erbB4 gene was expressed in HCS-2/
8, a human chondrocytic cell line. Furthermore, we demon-
strated that erbB4 gene was expressed in chondrocytes in
growth and articular cartilage. There have been no previous
reports describing the expression of the erbB4 gene in connec-
tive tissue. This is partly because ErbB4 [21], a NRG receptor,
has been believed to be one of the neural tissue-speci¢c fac-
tors. However, our study suggests another novel biological
role of ErbB4, one in cartilaginous tissues.
The possible contribution of neurotrophic factors and their
receptors in the growth and development of chondrocytes has
been previously described in a few reports. Such ¢ndings are
typically represented by the case of neurotrophins during the
bone regeneration process. In a mouse longitudinal bone frac-
ture model, neurotrophins such as nerve growth factor, brain-
derived neurotrophic factor, and neurotrophin-3 were specif-
ically expressed in bone-forming cells, together with their spe-
ci¢c receptors tropomycsin receptor kinase (TRK) A and
TRKC, suggesting their active function in bone reconstruction
[22]. Whereas the roles of these neural factors and their re-
ceptors in the bone regeneration process still remain to be
clari¢ed, their functions in neurons have been well-character-
ized; and it is known that they promote both di¡erentiation
and survival of neuronal cells. Interestingly, similar e¡ects on
neuronal tissues were conferred also by NRG, the ErbB4 li-
gand [23]. Considering the functional similarity between NRG
and neurotrophins in neuronal tissues, it seems reasonable
that NRG would contribute also to the formation and main-
tenance of connective tissues, which actions may be mediated
by ErbB4. Therefore, roles of NRG/ErbB4 in endochondral
ossi¢cation, articular cartilage maintenance, and fracture heal-
ing should be investigated in the near future.
Fig. 4. Expression of erbB4 gene in cartilage in vivo. Normal mouse
femur growth plate and temporomandibular joint were analyzed by
in situ hybridization with speci¢c probes against erbB4 and ctgf. Ex-
pression of the erbB4 gene is observed throughout all of the stages
of di¡erentiating chondrocytes in the growth plate (A: right panel).
In articular cartilage (B: left panel) erbB4-positive cells are found
sporadically near the joint surface, and more prominent erbB4 ex-
pression is observed among more di¡erentiated chondrocytes inside.
Similarly, the distribution of ctgf-positive cells is restricted to rela-
tively di¡erentiated articular chondrocyte layers (B: right panel).
Control experiments with sense riboprobes for erbB4 (A: left panel)
and ctgf (data not shown) gave no signi¢cant signals.
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Whether the ErbB4 ligand NRG is actually expressed in
normal cartilage and fracture healing process, or not, is un-
clear. However, interestingly, CTGF/Hcs24 was recently
found to be expressed during fracture healing as well as in
normal cartilage [26]. While pursuing CTGF/Hcs24 receptors,
we re-discovered ErbB4 as a chondrocytic receptor mediating
certain signaling. To date, several cell-surface receptors have
been reported to interact with CTGF/Hcs24, but none of
them have been shown to transduce signals into the cells
through a phosphorylation cascade. However, it was already
proven that CTGF/Hcs24 is capable of activating a signal
transduction cascade mediated by mitogen-activated protein
kinases in chondrocytes [24]. ErbB4 is a tyrosine kinase-type
receptor, and we found that erbB4 gene expression was upreg-
ulated by the CTGF/Hcs24 signal. Only with such indirect
¢ndings, we ought to avoid to conclude that ErbB4 is one
of the speci¢c receptors of CTGF/Hcs24. Thus, direct binding
between ErbB4 and CTGF/Hcs24 molecules is currently being
evaluated. Also, the mechanism by which erbB4 is expressed
at earlier stages of chondrocyte di¡erentiation (Fig. 3) is un-
clear. Nevertheless, it may be ascribed to the compensatory
e¡ect by the Cyr61 molecules which is structurally and func-
tionally quite similar to CTGF/Hcs24. Of note, Cyr61 was
reported to be expressed during early stages of chondrogenesis
[25]. Therefore, comparative investigation of CTGF/Hcs24
and Cyr61 is of critical importance for comprehensive under-
standing of the function of these factors in cartilage. However,
it is already clear that ErbB4 should play some biological
role(s) in chondrocytes in vivo. Knocking out the erbB4 genes
in mice and cartilage-oriented analysis of these animals may
give us remarkable insights into the function of ErbB4 in
cartilaginous tissues as well as in neuronal tissues.
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